• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Decoding the immune landscape: and genes mutations shape CD8 T cell response in resectable non-small-cell lung cancer after neoadjuvant therapy.

作者信息

Wojas-Krawczyk Kamila, Knetki-Wróblewska Magdalena, Krzakowski Maciej

机构信息

Pneumonology, Oncology and Allergology Department, Medical University in Lublin, Lublin, Poland.

Lung Cancer and Chest Tumours Department, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

出版信息

Transl Lung Cancer Res. 2025 Aug 31;14(8):2918-2921. doi: 10.21037/tlcr-2025-442. Epub 2025 Aug 20.

DOI:10.21037/tlcr-2025-442
PMID:40948840
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12432620/
Abstract
摘要

相似文献

1
Decoding the immune landscape: and genes mutations shape CD8 T cell response in resectable non-small-cell lung cancer after neoadjuvant therapy.解码免疫格局：基因变异如何塑造新辅助治疗后可切除非小细胞肺癌中的CD8 T细胞反应。
Transl Lung Cancer Res. 2025 Aug 31;14(8):2918-2921. doi: 10.21037/tlcr-2025-442. Epub 2025 Aug 20.
2
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.新辅助免疫检查点阻断治疗后，可切除的KRAS突变型肺癌中基于STK11共突变状态的不同临床和免疫结果。
Clin Cancer Res. 2025 Jan 17;31(2):339-351. doi: 10.1158/1078-0432.CCR-24-2983.
3
gene therapy induces effective antitumor immunity in mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model.在人源化小鼠模型中，基因疗法可在抗程序性死亡蛋白1（PD1）耐药的转移性非小细胞肺癌（NSCLC）突变体中诱导有效的抗肿瘤免疫。
Elife. 2025 Feb 11;13:RP98258. doi: 10.7554/eLife.98258.
4
Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.真实世界环境中，存在 STK11 和/或 KEAP1 突变的情况下，KRAS G12C 突变的晚期非小细胞肺癌患者的总生存期。
BMC Cancer. 2023 Apr 17;23(1):352. doi: 10.1186/s12885-023-10778-6.
5
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer.可操作的基因组改变对可切除非小细胞肺癌新辅助免疫治疗疗效的影响。
J Immunother Cancer. 2024 Oct 23;12(10):e009677. doi: 10.1136/jitc-2024-009677.
6
The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer.致癌驱动基因突变对可切除非小细胞肺癌患者新辅助免疫治疗结局的影响。
Cancer Immunol Immunother. 2023 Dec;72(12):4235-4247. doi: 10.1007/s00262-023-03560-x. Epub 2023 Nov 6.
7
A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol.一项关于新辅助Opnurasib（KRAS G12C抑制剂）治疗可手术切除的非小细胞肺癌患者的II期研究（CCTG IND.242A）：IND.242平台主方案的一项子研究
Clin Lung Cancer. 2025 Mar;26(2):146-151. doi: 10.1016/j.cllc.2024.09.003. Epub 2024 Sep 20.
8
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer.新辅助PD-1和PD-L1阻断联合化疗治疗可切除边缘和不可切除的III期非小细胞肺癌
JAMA Oncol. 2025 May 22. doi: 10.1001/jamaoncol.2025.1115.
9
Neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer with driver mutations: a retrospective analysis.新辅助免疫治疗联合化疗用于可切除的驱动基因突变非小细胞肺癌：一项回顾性分析
Front Immunol. 2025 Aug 27;16:1637615. doi: 10.3389/fimmu.2025.1637615. eCollection 2025.
10
Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS-Induced Immunogenicity in Patients with Non-Small Cell Lung Cancer.抑癌基因 STK11 缺失抑制非小细胞肺癌患者的脂代谢并减弱 KRAS 诱导的免疫原性。
Cancer Res Commun. 2024 Aug 1;4(8):2282-2294. doi: 10.1158/2767-9764.CRC-24-0153.

本文引用的文献

1
Four-year outcomes with perioperative toripalimab plus chemotherapy in resectable stage III non-small cell lung cancer (NeoTAP01 study).围手术期托瑞帕利单抗联合化疗用于可切除Ⅲ期非小细胞肺癌的4年结局（NeoTAP01研究）
J Thorac Dis. 2025 May 30;17(5):2947-2957. doi: 10.21037/jtd-2024-2266. Epub 2025 May 28.
2
Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLC.STK11、KEAP1和SMARCA4基因拷贝缺失：非鳞状非小细胞肺癌的临床病理特征及其与免疫治疗联合或不联合化疗疗效的相关性
J Thorac Oncol. 2025 Jan 27. doi: 10.1016/j.jtho.2025.01.016.
3
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.
新辅助免疫检查点阻断治疗后，可切除的KRAS突变型肺癌中基于STK11共突变状态的不同临床和免疫结果。
Clin Cancer Res. 2025 Jan 17;31(2):339-351. doi: 10.1158/1078-0432.CCR-24-2983.
4
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.度伐利尤单抗联合或不联合曲美木单抗与化疗联用治疗一线转移性非小细胞肺癌：3期POSEIDON试验的5年总生存结果
J Thorac Oncol. 2025 Jan;20(1):76-93. doi: 10.1016/j.jtho.2024.09.1381. Epub 2024 Sep 5.
5
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer.早期可切除 NSCLC 的新辅助和辅助治疗：国际肺癌研究协会的共识建议。
J Thorac Oncol. 2024 Oct;19(10):1373-1414. doi: 10.1016/j.jtho.2024.06.010. Epub 2024 Jun 18.
6
Perioperative Nivolumab in Resectable Lung Cancer.可切除肺癌的围手术期纳武利尤单抗。
N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926.
7
Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels.KRAS 突变和 STK11/KEAP1 共突变的晚期 NSCLC 患者一线免疫检查点抑制（ICI）治疗的结局与 PD-L1 水平的关系。
Lung Cancer. 2024 Apr;190:107510. doi: 10.1016/j.lungcan.2024.107510. Epub 2024 Feb 24.
8
The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer.致癌驱动基因突变对可切除非小细胞肺癌患者新辅助免疫治疗结局的影响。
Cancer Immunol Immunother. 2023 Dec;72(12):4235-4247. doi: 10.1007/s00262-023-03560-x. Epub 2023 Nov 6.
9
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.可切除非小细胞肺癌的围手术期度伐利尤单抗治疗。
N Engl J Med. 2023 Nov 2;389(18):1672-1684. doi: 10.1056/NEJMoa2304875. Epub 2023 Oct 23.
10
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.帕博利珠单抗用于早期非小细胞肺癌的围手术期治疗。
N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3.